Back to Authors

Stamm, Brian

0000-0002-0862-9650

Mayo Clinic

Department of Neurology, VA Center for Clinical Management Research, University of Michigan, Ann Arbor.

Citations 3

Real-World Practice in Secondary Stroke Prevention Following Embolic Stroke of Undetermined Source

Neurology Clinical Practice | July 10, 2026 | Volume: 16 | Issue: 4 | Pages: No page available

10.1212/cpj.0000000000200631 | PMID 42430672

Intracranial Occlusion in Cryptogenic Stroke Is Not Predictive of Recurrent Ischemic Stroke: A Propensity‐Score Matched Analysis of the Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence Study

Journal of the American Heart Association | September 25, 2025 | Volume: 14 | Issue: 19 | Pages: No page available

10.1161/jaha.125.041500 | PMID 40996035

Background Intracranial occlusions in embolic stroke of undetermined source are histopathologically similar to cardiac sources of embolism. Whether patients with embolic stroke of undetermined source and intracranial occlusion benefit from anticoagulation is unknown. Methods A multicenter retrospective cohort of adults with cryptogenic stroke was queried for patients with proximal or medium/distal vessel occlusion. The primary outcome was recurrent ischemic stroke, which was assessed in unadjusted and adjusted Cox proportional hazards models and repeated following 1:1 propensity score matching and biweight kernel density matching. Results Of the 2328 patients who were followed over a median of 1.31 years (interquartile range, 0.34–2.85), 999 (42.6%) had an intracranial occlusion. When compared with patients without an intracranial occlusion, those with an occlusion had fewer atherosclerotic vascular risk factors, more severe symptoms, and less severe cerebral microvascular disease. The rate of recurrent stroke was similar between patients with versus without an intracranial occlusion (6.8%/year [95% CI, 5.7–8.2] versus 7.0%/year [95% CI 6.0–8.1]; adjusted hazard ratio [HR], 1.09 [95% CI, 0.77–1.55]). There was no association between occlusion and recurrent stroke in the adjusted propensity score matching (HR, 1.01 [95% CI, 0.64–1.59]) or kernel density models (HR, 0.95 [95% CI, 0.62–1.45]). There was no interaction between occlusion and treatment with anticoagulation, sex, age, or high‐risk sources of embolism for the primary outcome in the unmatched and matched analyses. Conclusions Intracranial occlusion in patients with embolic stroke of undetermined source is not associated with a greater risk of recurrence when compared with patients without an intracranial occlusion. There was no difference in rate of recurrent stroke with anticoagulation when stratified by presence or absence of occlusion.
Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation

Neurology | July 3, 2025 | Volume: 105 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000213876 | PMID 40609061